Journal of Clinical Endocrinology & Metabolism最新文献

{"title":"Letter to the Editor from Lin et al.: \"Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial\".","authors":"Kuo-Jen Lin, I-Hung Shao, Yu-Hsiang Lin","doi":"10.1210/clinem/dgaf066","DOIUrl":"https://doi.org/10.1210/clinem/dgaf066","url":null,"abstract":"","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Response to Letter to the Editor from Lin et al.: \"Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial\".","authors":"Mathis Grossmann, Kristy P Robledo, Mark Daniel, David J Handelsman, Warrick J Inder, Bronwyn G A Stuckey, Bu B Yeap, Mark Ng Tang Fui, Karen Bracken, Carolyn A Allan, David Jesudason, Jeffrey D Zajac, Gary A Wittert","doi":"10.1210/clinem/dgaf067","DOIUrl":"https://doi.org/10.1210/clinem/dgaf067","url":null,"abstract":"","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing OGTT: Unlocking the Real-time Insights and Expanded Data of Continuous Glucose Monitoring (CGM).","authors":"Sujatha Seetharaman, Laya Ekhlaspour","doi":"10.1210/clinem/dgaf068","DOIUrl":"https://doi.org/10.1210/clinem/dgaf068","url":null,"abstract":"","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Houston We Have a Problem….\": Raising the Quality and Authenticity of Manuscripts Submitted to JCEM.","authors":"Paul M Stewart","doi":"10.1210/clinem/dgaf036","DOIUrl":"https://doi.org/10.1210/clinem/dgaf036","url":null,"abstract":"","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone Health and Linear Growth in Children with Familial Hypoparathyroidism Treated with Human Parathyroid Hormone 1-34.","authors":"Karen K Winer, Babette S Zemel, Andrea Kelly, James C Reynolds, Joseph Pechacek, Taura Webb, Didier Hans, Michail S Lionakis, Heidi J Kalkwarf","doi":"10.1210/clinem/dgaf065","DOIUrl":"https://doi.org/10.1210/clinem/dgaf065","url":null,"abstract":"<p><strong>Context: </strong>Our study explores the impact of human PTH 1-34 injections (PTH therapy) on growth, areal bone mineral density (BMD), and bone quality (measured by trabecular bone score, TBS) in hypoparathyroidism due to autoimmune polyendocrine syndrome type 1 (APS-1) or an activating variant of the calcium sensing receptor (CaR).</p><p><strong>Objective: </strong>To assess associations of 1) age and PTH therapy duration with age-standardized Z-scores for height (HAZ), BMD (BMD-Z), and TBS (TBS-Z) in CaR or APS-1, and 2) APS-1 disease severity with BMD-Z and TBS-Z.</p><p><strong>Methods: </strong>This secondary analysis pooled linear growth and lumbar spine (LS) DXA data from studies of hypoparathyroidism with mean baseline age of 13.7±5.5y. Comparing the two diagnostic etiologies (18 APS-1 and 9 CaR), we examined the impact of age and PTH duration on HAZ, LS-BMD-Z, and LS-TBS-Z using longitudinal mixed-effects modeling.</p><p><strong>Results: </strong>During PTH therapy, mean HAZ remained below zero in the APS-1 group at all ages, whereas HAZ increased in the CaR group (age by group interaction p<0.0001). Mean LS-BMD-Z were normal (BMD-Z:0±1) for both groups. Mean LS-TBS-Z were near or above zero and differed by group; CaR showed an upward trajectory according to time on PTH whereas the APS-1 group maintained a LS-TBS-Z of approximately 0 (time by group interaction p=0.02). The APS-1 group with greater disease severity (≥7 manifestations) had lower LS-BMD-Z and LS-TBS-Z compared to the less severe APS-1 or CaR groups.</p><p><strong>Conclusion: </strong>Our study highlights distinct growth and BMD patterns in APS-1 and CaR and underscores the need for careful monitoring and tailored treatment strategies to optimize growth and bone health.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2,333,496 Patients from the TriNetX Network.","authors":"Kai-Lun Cheng, Wei-Shin Yu, Yu-Hsun Wang, Gema Hernández Ibarburu, Hsiang-Lin Lee, James Cheng-Chung Wei","doi":"10.1210/clinem/dgaf064","DOIUrl":"https://doi.org/10.1210/clinem/dgaf064","url":null,"abstract":"<p><strong>Context: </strong>Reports on long-term thyroid dysfunction following COVID-19 vaccination are limited. Understanding the risk of subacute thyroiditis, hyperthyroidism, and hypothyroidism in vaccinated individuals is crucial for post-vaccination monitoring.</p><p><strong>Objective: </strong>This study evaluated the risk of thyroid dysfunction in COVID-19 vaccinated individuals compared to unvaccinated individuals using a large cohort.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study from January 1, 2022, to December 31, 2023, using the TriNetX database, including 1,166,748 vaccinated and 1,166,748 unvaccinated individuals. Propensity score matching was used to balance baseline characteristics. The primary outcomes were new diagnoses of subacute thyroiditis, hyperthyroidism, and hypothyroidism.</p><p><strong>Results: </strong>The risk of subacute thyroiditis remained unchanged (95% confidence intervals [CIs] included 1). A significant reduction in hyperthyroidism risk was observed from 3 to 9 months post-vaccination (hazard ratios [HRs]: 0.65-0.89, all 95% CIs below 1), but this trend was not significant at 12 months (HR: 0.99, 95% CI: 0.92-1.06). In contrast, the risk of hypothyroidism significantly increased from 6 to 12 months post-vaccination (HR: 1.14-1.30, all 95% CIs above 1). Among mRNA vaccine recipients, the risk of both hyperthyroidism and hypothyroidism was significantly elevated at 12 months (HR: 1.16-2.13).</p><p><strong>Conclusion: </strong>COVID-19 vaccination was associated with a reduced risk of hyperthyroidism and an increased risk of hypothyroidism, highlighting the need for ongoing thyroid function monitoring.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic Profiles of Pregnancy with Polycystic Ovary Syndrome: Insights into Maternal-Fetal Metabolic Communication.","authors":"Huisheng Ge, Dongni Huang, Lunbo Tan, Dan Luo, Liu Zhou, Hong Liu, Yilan Zhang, Dandan Liu, Xixi Wu, Lulu Wang, Liling Xiong, Yang Yang, Ting-Li Han, Chengjin He, Hongbo Qi","doi":"10.1210/clinem/dgaf057","DOIUrl":"https://doi.org/10.1210/clinem/dgaf057","url":null,"abstract":"<p><strong>Context: </strong>PCOS pregnancies are linked to metabolic disorders affecting maternal and fetal outcomes, with maternal metabolites differing from those in normal pregnancies.</p><p><strong>Objective: </strong>To investigate the metabolic communication at the maternal-fetal interface in PCOS pregnancies.</p><p><strong>Design: </strong>Placenta and umbilical cord serum were analyzed using gas chromatography-mass spectrometry. In-depth analysis was performed with clinical characteristics.</p><p><strong>Setting: </strong>Placenta and umbilical cord serum were analyzed using gas chromatography-mass spectrometry, alongside clinical characteristics.</p><p><strong>Participants: </strong>45 uncomplicated PCOS pregnancies and 50 normal pregnancies.</p><p><strong>Intervention(s): </strong>None.</p><p><strong>Main outcome measure(s): </strong>The metabolic characteristics at the maternal-fetal interface in PCOS pregnancies and the underlying mechanisms.</p><p><strong>Results: </strong>A total of 79 metabolites in the placenta and 25 in umbilical cord serum showed significant differences between polycystic ovary syndrome (PCOS) and normal pregnancies. The 10 most significant placental metabolites were identified through receiver operating characteristic (ROC) analysis, 9 of which correlated significantly with maternal serum testosterone levels. Lasso regression analysis identified 4 key placental metabolite combinations: gamma-aminobutyric acid, proline, glycine, and isoleucine, achieving an area under the curve (AUC) of 93.24%. In umbilical cord serum, 6 metabolites differed significantly between PCOS and normal pregnancies, with the highest AUC reaching 76.07%, and 5 of these metabolites showed significant correlations with maternal serum testosterone levels. Nine differential metabolites were shared between the placenta and umbilical cord serum, which also shared metabolic pathways, including ABC transporters and aminoacyl-tRNA biosynthesis, potentially influencing maternal-fetal interactions.</p><p><strong>Conclusion: </strong>This study identifies the metabolomic profile and key pathways in maternal-fetal communication during PCOS pregnancies.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiofrequency ablation for thyroid nodules (RATED study) - analysis of a learning curve and predictors of success.","authors":"Manon M D van der Meeren, Tim Boers, Pim de Graaf, Katya M Duvivier, Koen M A Dreijerink, Laura N Deden, Peter Veendrick, Paul Cernohorsky, Frank B M Joosten, Angelique B M C Savelberg, Sicco J Braak, Sean H P P Roerink, Michel Versluis, Srirang Manohar, Wim J G Oyen","doi":"10.1210/clinem/dgaf058","DOIUrl":"https://doi.org/10.1210/clinem/dgaf058","url":null,"abstract":"<p><strong>Context: </strong>Radiofrequency ablation (RFA) is used as treatment for symptomatic thyroid nodules. Factors influencing the volume reduction ratio (VRR) at 12 months are not yet fully understood.</p><p><strong>Objective: </strong>The primary objective was evaluating the VRR at 12 months after RFA. Secondary objectives were the assessment of a learning curve and factors influencing the VRR at 12 months.</p><p><strong>Design: </strong>A retrospective observational cohort study.</p><p><strong>Setting: </strong>Three Dutch referral hospitals.</p><p><strong>Patients and intervention: </strong>Patients who underwent RFA for symptomatic thyroid nodules with available ultrasound follow-up.</p><p><strong>Main outcome measures: </strong>Ultrasound based VRR at 12 months and chronologically numbered RFA procedures. All patients' baseline, treatment, and early follow-up factors were assessed for correlation with VRR at 12 months.</p><p><strong>Results: </strong>A total of 337 patients with 356 nodules were included in the learning curve analysis. VRR at 12 months increases for the first 20 treatments per center and stabilizes thereafter, indicating a plateau phase after a learning curve. These initial cases were removed from further analysis. In the remaining 299 nodules, median VRR at 3, 6 and 12 months was 57.1, 65.6 and 70.8%. Baseline nodule volume negatively correlated with VRR at 12 months but VRR was high for every volume category. Energy delivered per volume did not correlate to VRR.</p><p><strong>Conclusions: </strong>In RFA for thyroid nodules a stable treatment efficacy is achieved after 20 treatments, with a median VRR of 70.8%. Baseline nodule volume, energy delivered and prolonged follow-up 6 months after treatment may not be clinically relevant to predict treatment success.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Neuroendocrine Regulation of Reproductive Behavior and Emotional Control by Kisspeptin.","authors":"Edouard G Mills, Jovanna Tsousouki, Aureliane C S Pierret, Alexander N Comninos, Waljit S Dhillo","doi":"10.1210/clinem/dgaf055","DOIUrl":"https://doi.org/10.1210/clinem/dgaf055","url":null,"abstract":"<p><p>Reproductive success and ultimately species survival at a population level is contingent on a plethora of neuroendocrine signals working in concert to regulate gonadal function and reproductive behavior. Among these, the neuropeptide kisspeptin (encoded by the KISS1/Kiss1 gene) has emerged as the master regulator of the hypothalamic-pituitary-gonadal axis. Besides the hypothalamus, both kisspeptin and its cognate receptor are extensively expressed throughout cortico-limbic brain structures in rodents and humans, which are regions traditionally implicated in behavioral and emotional responses. Thus, there exists a neuroanatomical framework through which kisspeptin can integrate reproductive behavior and emotional regulation with the reproductive axis. Accordingly, this sets the scene for recent findings derived from an assortment of species, including humans, unveiling kisspeptin as an important gatekeeper of reproductive behavior and emotional control. Herein, we summarize the major preclinical animal and human experimental evidence identifying kisspeptin as a key neuromodulator of reproductive behavior and emotional state. Such findings have laid the foundations for clinical applications of kisspeptin-based therapies for patients with related reproductive and psychosexual disorders.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The natural history of cytologically low-risk indeterminate thyroid nodules.","authors":"Marsida Teliti, Spyridon Chytiris, Francesca Coperchini, Matteo Cerutti, Beatrice Grillini, Maria Gallo, Benedetto Calì, Giovanni Arpa, Mario Rotondi, Flavia Magri","doi":"10.1210/clinem/dgaf052","DOIUrl":"https://doi.org/10.1210/clinem/dgaf052","url":null,"abstract":"<p><strong>Background: </strong>Thyroid nodules classified cytologically as low-risk indeterminate lesions (TIR3A) on fine-needle aspiration biopsy (FNAB) present a clinical challenge due to their uncertain malignancy risk. This single-center study aimed to evaluate the natural history of TIR3A nodules.</p><p><strong>Materials and methods: </strong>FNABs performed between July 2017 and December 2019 were retrospectively retrieved and patients with TIR3A nodules were evaluated at baseline and throughout a follow-up based on ultrasound (US) parameters and clinical data.</p><p><strong>Results: </strong>The final study group encompassed 371 patients with an initial TIR3A cytological result. Among them 102 were addressed to surgery after the first endocrinological evaluation, and 269 were addressed to conservative follow-up. Repeat FNAB was performed in 120 out of 269 and 13 further patients underwent surgery following FNAB repetition. The malignancy rate among TIR3A nodules was 16.5%, with most interventions being performed for reasons unrelated to the TIR3A result. Repeat FNAB provided a more definitive diagnosis in 40% of cases, with a 5% increase in malignancy risk. The remaining patients were monitored with clinical and US follow-up. Among all patients with TIR3A cytology managed conservatively (149 without FNAB repetition and 66 with at least one FNAB repetition), no significant changes in nodule size and/or US pattern were observed during a median follow-up of 3.3 years.</p><p><strong>Conclusions: </strong>These findings suggest that active surveillance is a safe option for managing TIR3A nodules, particularly when no additional risk factors are present. The study highlights the role of repeat FNAB in reducing unnecessary surgeries and underscores the generally indolent nature of TIR3A nodules.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}